BERKELEY, Calif.--(BUSINESS WIRE)--Dynavax Technologies Corporation (Nasdaq:DVAX) today announced that an abstract with chronic kidney disease patient data for HEPLISAVTM, an investigational adult hepatitis B vaccine, will be presented at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) in Philadelphia, Pennsylvania, from October 29 through November 1, 2009.
